Rowan Gardner is a seasoned entrepreneur and CEO with over 30 years of experience in health tech, digital health, deep tech, and biotech. She played a part in one of Oxford University's first spin-outs, Oxford Molecular Group, in 1989 and later listed it on the main London Stock Exchange in 1994. Rowan is a fervent advocate for Oxford and currently serves as the Chief Business and Investment Officer at Precision Life. This platform connects chronic disease patients with the drugs they'll respond to, using mechanistic patient stratification biomarkers.